Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1992 1
1993 1
1994 2
1995 2
1997 2
1998 1
2000 1
2001 1
2005 1
2006 2
2007 1
2009 1
2010 2
2011 1
2013 2
2014 3
2015 5
2016 4
2017 5
2018 5
2019 5
2020 14
2021 9
2022 11
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Sorafenib for the treatment of breast cancer.
Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati C, Amadori D, Rocca A. Bronte G, et al. Among authors: maltoni r. Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7. Expert Opin Pharmacother. 2017. PMID: 28335647 Review.
Androgen receptor in breast cancer: The "5W" questions.
Ravaioli S, Maltoni R, Pasculli B, Parrella P, Giudetti AM, Vergara D, Tumedei MM, Pirini F, Bravaccini S. Ravaioli S, et al. Among authors: maltoni r. Front Endocrinol (Lausanne). 2022 Aug 30;13:977331. doi: 10.3389/fendo.2022.977331. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36111296 Free PMC article. Review.
Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S, Limarzi F, Tumedei MM, Palleschi M, Maltoni R, Bravaccini S. Ravaioli S, et al. Among authors: maltoni r. Cancer Immunol Immunother. 2020 Oct;69(10):1943-1945. doi: 10.1007/s00262-020-02682-w. Epub 2020 Jul 28. Cancer Immunol Immunother. 2020. PMID: 32725361
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
Bravaccini S, Ravaioli S, Tumedei MM, Rocca A, Palleschi M, Puccetti M, Parrella P, Altini M, Maltoni R. Bravaccini S, et al. Among authors: maltoni r. Clin Cancer Res. 2020 Jul 15;26(14):3892-3893. doi: 10.1158/1078-0432.CCR-20-0668. Clin Cancer Res. 2020. PMID: 32669274 No abstract available.
CTCs in early breast cancer: A path worth taking.
Maltoni R, Gallerani G, Fici P, Rocca A, Fabbri F. Maltoni R, et al. Cancer Lett. 2016 Jul 1;376(2):205-10. doi: 10.1016/j.canlet.2016.03.051. Epub 2016 Apr 6. Cancer Lett. 2016. PMID: 27060205 Review.
CAR T cells targeting options in the fight against multiple myeloma.
Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, MartÍn-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C. Nicolini F, et al. Among authors: maltoni r. Panminerva Med. 2021 Mar;63(1):37-45. doi: 10.23736/S0031-0808.20.04146-4. Epub 2020 Sep 21. Panminerva Med. 2021. PMID: 32955187 Free article. Review.
Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A. Pietri E, et al. Among authors: maltoni r. Endocr Relat Cancer. 2016 Oct;23(10):R485-98. doi: 10.1530/ERC-16-0190. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528625 Review.
82 results